← All trials
NCT04584567
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Mar 1, 2021
- First posted
- Oct 14, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 1100
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of TunisiaLead sponsor
- Dacima ConsultingCollaborator
- Direction de la Santé militaireStudy chair
- Government of TunisiaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.